This story was originally published about Biopharma Dive. To receive daily news and insights, subscribe to our free daily biopharma -dive newsletter.
Today a short overview of news with Novo Nordisk, Acelyyrin and intracellular therapies, as well as updates from Gilead Sciences and Phrma that you might have missed.
The Food and Drug Administration has explained a shortage of two and a half years Novo Nordisk‘s Metabolic Medicines Ozempic For diabetes and Wegovy To ‘resolve’ obesity from Friday. The decision follows on the FDA’s statement of an end to Eli Lilly’s competing drugs Mounjaro and Zepbound. The two companies have struggled with capacity if the demand for drugs has risen, especially in obesity. To ensure that the stocks of composite alternatives of the NOVO drugs are not disturbed, the FDA said that until April 22 it will not enforce a ban on those products if it is manufactured in a pharmacy or 22 May being identified by the state if they are Authorized outsourcing facility are made on a federal. Shares in HIMS & HARE HEALTHThose composite versions of the medicines have brought to the market, fell by more than 20% in trade on Friday morning. – Jonathan Gardner
Concentrra cinemasAn entity that is checked by investment firm Tang Capital Partnershas expressed an unsolicited offer Acelyin Weeks after the company agreed to merge with colleagues -immune developer Lower. Through the offer announced on Thursday, Concentra is planning to acquire Acelyyrin for $ 3 per share in cash, as well as the right to 80% of the proceeds if Concentra likes whether the programs sell or sells. The shareholders of Acelyyrin would get around 45% of the shares of Alumis – which currently act around $ 5 each – in the planned merger. Acelyyrin said his administration will act in “the best interests of all shareholders” and that it will make a further announcement “in due course”. If approved by shareholders, the merger with alumis would close in the second quarter. – I Fidler
Intracellular therapiesMaker of the Spirit-Stabilizing Medicine CaplytaIt reported on Friday that the net turnover of the product last year was almost $ 681 million. That sum is an increase of 47% compared to 2023. Caplyta has already been approved in the US as a treatment for schizophrenia and bipolar depression, and can be deleted in severe depression for too long. Feeling the blockbuster -potential of the medicine, Johnson & Johnson Recently agreed to acquire intra-cellularly for nearly $ 15 billion. The deal is expected to close later this year. – Jacob Bell
